Pharma

Novo Nordisk Unveils Promising Weight Loss Results from Amycretin Clinical Trial

Innovative GLP-1 and amylin receptor agonist shows up to 22% weight reduction in early-stage study.

Novartis' Intrathecal Onasemnogene Abeparvovec Phase III Study Meets Primary Endpoint

Novartis' Phase III study of intrathecal onasemnogene abeparvovec for spinal muscular atrophy (SMA) successfully met its primary endpoint, showing significant motor function improvements.

GSK’s Nucala Approved in China for Treatment of Adults with Chronic Rhinosinusitis with Nasal Polyps

GSK’s Nucala has been approved by China’s National Medical Products Administration for the treatment of adults with chronic rhinosinusitis with nasal polyps, offering a new therapeutic option for patients.

2025: A Year of Promise in Pharma and Biotech — Key Trials and Drug Candidates to Watch

The BioFocus Editorial Team recap key developments from 2024 and highlight some of the most promising clinical trials and emerging therapies to keep an eye on.

Vertex Announces FDA Approval of ALYFTREK™ for Cystic Fibrosis Treatment

Vertex Pharmaceuticals has announced a major milestone in the treatment of cystic fibrosis (CF) with the U.S. FDA approval of ALYFTREK™, a once-daily triple combination therapy.

Merck Partners with Hansoh Pharma on Oral GLP-1 Receptor Agonist for Type 2 Diabetes

Merck has entered into an exclusive global license agreement with Hansoh Pharma to develop and commercialize HS-10270, an investigational oral GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity.